JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 57(2023) N 6 p. 1228-1238; DOI 10.1134/S0026893324010175 Full Text

Y.W. Wang1, K.G. Jia2, H.J. Xing3, Y. Pan4, C.S. Zeng3, L. Chen3, Q.J. Su3, W.T. Shen5, J. Chen6, C. Chen3*, Q. Cao7, Y.Y. Wang2**

Interaction of SENP6 with PINK1 Promotes Temozolomide Resistance in Neuroglioma Cells via Inducing the Mitophagy

1School of Medicine of University of Electronic Science and Technology of China, Chengdu, 611730 People's Republic of China
2Department of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610031 People's Republic of China
3Department of Neurology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, 570100 People's Republic of China
4Department of Pharmacy, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, 570100 People's Republic of China
5Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510280 People's Republic of China
6Department of Neurology, Danzhou People's Hospital, Danzhou, Hainan Province, 571700 People's Republic of China
7Department of Assisted Reproductive Medicine, Sichuan Provincial Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, 611730 People's Republic of China

*315chencong@163.com
**Wangyouyu121@163.com
Received - 2023-03-05; Revised - 2023-05-09; Accepted - 2023-05-19

Temozolomide resistance is a major cause of recurrence and poor prognosis in neuroglioma. Recently, growing evidence has suggested that mitophagy is involved in drug resistance in various tumor types. However, the role and molecular mechanisms of mitophagy in temozolomide resistance in glioma remain unclear. In this study, mitophagy levels in temozolomide-resistant and -sensitive cell lines were evaluated. The mechanisms underlying the regulation of mitophagy were explored through RNA sequencing, and the roles of differentially expressed genes in mitophagy and temozolomide resistance were investigated. We found that mitophagy promotes temozolomide resistance in glioma. Specifically, small ubiquitin-like modifier specific protease 6 (SENP6) promoted temozolomide resistance in glioma by inducing mitophagy. Protein-protein interactions between SENP6 and the mitophagy executive protein PTEN-induced kinase 1 (PINK1) resulted in a reduction in small ubiquitin-like modifier 2 (SUMO2)ylation of PINK1, thereby enhancing mitophagy. Our study demonstrates that by inducing mitophagy, the interaction of SENP6 with PINK1 promotes temozolomide resistance in glioblastoma. Therefore, targeting SENP6 or directly regulating mitophagy could be a potential and novel therapeutic target for reversing temozolomide resistance in glioma.

glioblastoma, temozolomide resistance, SENP6, mitophagy, PINK1



JMB-FOOTER RAS-JOURNALS